Fermion has received CEP for salmeterol xinafoate

Salmeterol xinafoate is the 2nd long-acting β2 adrenergic receptor agonist API for which Fermion received CEP after formoterol fumarate dihydrate approval in 2015. Both products demonstrate Fermion's know-how in particle size engineering and effectiveness of new micronization capabilities.

Read more about Fermion's micronization